FrancophonIA/ELRC3.0 huggingface dataset:
English: The most frequently reported side effects were symptoms affecting the gut (diarrhoea, constipation, nausea and vomiting), headache, dizziness and hypotension (low blood pressure), all occurring in less than 2.5% of patients.
Estonian: Kõige sagedamad teatatud kõrvalnähud olid soolestikusümptomid (kõhulahtisus, kõhukinnisus, iiveldus ja oksendamine), peavalu, peapööritus ja hüpotensioon (madal vererõhk), mis kõik esinesid vähem kui 2,5%-l patsientidest.
English: Other information about Rienso
Estonian: Muu teave Rienso kohta
English: This is a summary of the European public assessment report (EPAR) for Rienso.
Estonian: See on ravimi Rienso Euroopa avaliku hindamisaruande kokkuvõte.
English: The CHMP decided that Rienso's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Rienso kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: The main measure of effectiveness was how much haemoglobin levels (measured in grams per decilitre, g/dl) rose after five weeks.
Estonian: Efektiivsuse põhinäitaja oli hemoglobiinisisalduse suurenemine (mõõdeti grammides detsiliitri kohta, g/dl) viie nädala järel.
English: The increase in haemoglobin seen in the main studies was considered by the CHMP to be a valuable improvement and comparable to what is obtained with standard intravenous iron preparations.
Estonian: Inimravimite komitee pidas põhiuuringutes ilmnenud hemoglobiinisisalduse suurenemist heaks tulemuseks ning võrreldavaks sellega, mida on saavutatud standardravi intravenoossete rauapreparaatidega.
English: Serious cases of hypersensitivity (allergic reaction) or hypotension were uncommon and were seen in 0.2% of patients.
Estonian: Raske ülitundlikkus (allergiareaktsioon) või hüpotensioon esinesid harva, 0,2%-l patsientidest.
English: For more information about treatment with Rienso, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Riensoga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: In studies with Rienso, side effects were seen in 7.9% of patients taking the medicine, of which 0.2% were considered serious.
Estonian: Patsiente, kellel Rienso uuringutes ilmnes kõrvalnähte, oli 7,9%, neist 0,2%-l esines raskeid kõrvalnähte.
English: What is Rienso?
Estonian: Mis on Rienso?
English: It is available as a solution for infusion (drip) into a vein.
Estonian: Seda turustatakse infusioonilahusena (veeni tilgutatav lahus).
English: Rienso is given as an infusion into a vein lasting at least 15 minutes.
Estonian: Riensot manustatakse vähemalt 15 minutit kestva intravenoosse infusioonina.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Rienso, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Rienso omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Rienso.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: For the full list of all side effects reported with Rienso, see the package leaflet.
Estonian: Rienso kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: Rienso ferumoxytol
Estonian: Rienso ferumoksütool
English: With the iron stores replenished, the body can produce more haemoglobin, which will help correct the anaemia.
Estonian: Rauavarude täiendamine võimaldab organismil tekitada rohkem hemoglobiini ja seega ravida aneemiat.
English: Why has Rienso been approved?
Estonian: Miks Rienso heaks kiideti?
English: Rienso must not be used in people with a history of drug allergy, including allergy to ferumoxytol or any other iron preparation.
Estonian: Riensot ei tohi kasutada patsiendid, kellel on anamneesis ravimiallergia, sealhulgas allergia ferumoksütooli või mis tahes muu rauapreparaadi suhtes.
English: When injected into the blood, it is taken up by cells in the liver, spleen and the bone marrow, at which point the iron is released from the compound and replaces the body's depleted iron stores.
Estonian: Kui ravimit manustatakse infusioonina verre, neeldub see maksa-, põrna- ja luuüdirakkudes, kus raud vabaneb ühendist ning täiendab organismi vähenenud rauavarusid.
English: Iron deficiency is a common cause of anaemia in patients with long-term kidney disease and is itself caused by many factors including the poor absorption of dietary iron from food.
Estonian: Rauavaegus on kroonilise neeruhaigusega patsientide aneemia tavaline põhjus ja tuleneb paljudest teguritest, näiteks sellest, et toidus sisalduv raud imendub organismis halvasti.
English: Rienso is an iron preparation that contains the active substance ferumoxytol.
Estonian: Rienso on rauapreparaat, mille toimeaine on ferumoksütool.
English: What is the risk associated with Rienso?
Estonian: Mis riskid Riensoga kaasnevad?
English: In addition, the company that market Rienso will provide educational material to patients and doctors expected to use Rienso, with information on the risk of allergic reactions.
Estonian: Lisaks annab Rienso turustaja ravimit kasutavatele patsientidele ja arstidele allergiliste reaktsioonide riski teabematerjali.
English: Rienso is used to treat anaemia (low levels of red blood cells or haemoglobin) caused by a deficiency of iron in patients with chronic kidney disease (long-term, progressive decrease in the ability of the kidneys to work properly).
Estonian: Riensot kasutatakse rauavaegusest põhjustatud aneemia (punaliblede või hemoglobiini vähesus) raviks kroonilise neeruhaigusega (neerutalitluse pikaajaline süvenev halvenemine) patsientidel.
English: Three main studies involving 838 chronic kidney disease patients with iron deficiency anaemia have been carried out to compare Rienso with an iron treatment taken by mouth.
Estonian: Rienso ravi võrdlemiseks rauavaeguse suukaudse raviga korraldati kolm põhiuuringut, milles osales 838 kroonilise neeruhaigusega patsienti, kellel oli rauavaegusest tingitud aneemia.
English: Rienso should only be given when healthcare professionals trained to manage anaphylactic (severe allergic) reactions and full resuscitation facilities are available.
Estonian: Riensot tohib manustada üksnes anafülaktilise (raske allergilise) reaktsiooni ravis kogenud tervishoiutöötaja järelevalve all ja tingimustes, kus saab kasutada elustamisvahendeid.
English: How does Rienso work?
Estonian: Kuidas Rienso toimib?
English: Rienso was more effective at increasing haemoglobin levels than the iron treatment taken by mouth.
Estonian: Riensoga toimunud ravi oli hemoglobiinisisalduse suurendamisel efektiivsem kui rauavaeguse suukaudne ravi.
English: It must not be used in patients with evidence of excess iron in the body or in patients whose anaemia is not caused by iron deficiency.
Estonian: Riensot ei tohi kasutada patsientidel, kellel esineb raua liigsuse nähte või kelle aneemiat ei põhjusta rauavaegus.
English: What benefit has Rienso shown during the studies?
Estonian: Milles seisneb uuringute põhjal Rienso kasulikkus?
English: Patients should have their blood and iron levels tested after at least one month following treatment.
Estonian: Vähemalt üks kuu pärast ravi tuleb teha patsiendile vereanalüüs ja määrata vere rauasisaldus.
English: Rienso was shown to be superior to iron taken by mouth in treating iron deficiency anaemia in patients with chronic kidney disease.
Estonian: Tõestati, et Rienso on kroonilise neeruhaigusega patsientide rauavaegusest tingitud aneemia ravis efektiivsem kui suukaudsed rauapreparaadid.
English: The active substance in Rienso, ferumoxytol, is an iron-containing compound.
Estonian: Rienso toimeaine ferumoksütool on rauaühend.
English: What is Rienso used for?
Estonian: Milleks Riensot kasutatakse?
English: How is Rienso used?
Estonian: Kuidas Riensot kasutatakse?
English: How has Rienso been studied?
Estonian: Kuidas Riensot uuriti?
English: To maintain normal haemoglobin levels, patients may be re-treated with Rienso if they are confirmed to be lacking iron.
Estonian: Rauavaeguse korral tohib normaalse hemoglobiinisisalduse saavutamiseks teha patsiendile Rienso kordusravi.
English: 26 March 2010
Estonian: 26. märts 2010
English: The application was submitted in the framework of Article 32 of Directive 2001/82/EC, where the Reference Member State was France and the Concerned Member States were Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, The Netherlands, Poland, Portugal, Romania, Slovakia, Spain and United Kingdom.
Estonian: Taotlus esitati muudetud direktiivi 2001/82/EÜ artikli 32 kohaselt; viiteliikmesriik oli Prantsusmaa ning asjaomased liikmesriigid Austria, Belgia, Bulgaaria, Eesti, Hispaania, Iirimaa, Itaalia, Kreeka, Küpros, Leedu, Luksemburg, Läti, Madalmaad, Malta, Poola, Portugal, Rumeenia, Saksamaa, Slovakkia, Taani, Tšehhi Vabariik, Ungari ja Ühendkuningriik.
English: The Decentralised Procedure FR/V/195/01/DC started on 29 February 2008.
Estonian: Detsentraliseeritud menetlus FR/V/195/01/DC algas 29. veebruaril 2008.
English: The final opinion was converted into a Decision by the European Commission on 26 March 2010.
Estonian: Lõplik arvamus kinnitati Euroopa Komisjoni otsusena 26. märtsil 2010.
English: 1 Article 33(4) of Directive 2001/82/EC, as amended.
Estonian: 1 Muudetud direktiivi 2001/82/EÜ artikli 33 lõige 4.
English: The Rapporteur and Co-Rapporteur appointed were: Dr A. Holm and Dr B. Kolar, respectively.
Estonian: Määratud ettekandja ja kaasettekandja olid vastavalt dr A. Holm ja dr B. Kolar.
English: Oral explanations were given on 8 December 2009.
Estonian: Suulised selgitused anti 8. detsembril 2009.
English: The referral procedure started on 12 May 2009.
Estonian: Esildise menetlemine algas 12. mail 2009.
English: Written explanations were provided by the Applicant on 18 August 2009.
Estonian: Taotleja esitas kirjalikud selgitused 18. augustil 2009.
English: Toltrazuril is a triazinon derivative administered orally to piglets for the prevention of clinical signs of coccidiosis in neonatal piglets on farms with a confirmed history of coccidiosis caused by Isospora suis.
Estonian: Toltrazuril on triasinooniderivaat, mida manustatakse suu kaudu põrsastele, et ennetada vastsündinud põrsastel kliinilisi nähte majandites, milles on esinenud organismi Isospora suis tekitatud koktsidioosi kinnitatud juhte.
English: Based on the evaluation of the rapporteur's assessment of the currently available data, on 9 December 2009 the CVMP considered that the objections raised during the decentralised procedure should not prevent the granting of a Marketing Authorisation for CEVAZURIL 50 mg/ml oral suspension for piglets.
Estonian: Ettekandja hinnatud praegu kättesaadavate andmete läbivaatamise põhjal leidis veterinaarravimite komitee 9. detsembril 2009, et detsentraliseeritud menetluse käigus tõstatatud vastuväited ei takista andmast põrsaste ravimi CEVAZURIL 50 mg/ml suukaudse suspensiooni müügiluba.
English: The Applicant, Ceva Santé Animale, submitted an application for a decentralised procedure for CEVAZURIL 50 mg/ml oral suspension for piglets.
Estonian: Taotleja Ceva Santé Animale esitas põrsaste ravimi CEVAZURIL 50 mg/ml suukaudse suspensiooni detsentraliseeritud menetluse taotluse.
English: On 6 May 2009 France, referred the matter to the Agency under Article 33(4) of Directive 2001/82/EC, due to concerns, raised by Germany, Spain, Portugal, Poland and the United Kingdom, that the marketing authorisation of CEVAZURIL 50 mg/ml oral suspension for piglets may present a potential serious risk to the environment.
Estonian: 6. mail 2008 tegi Prantsusmaa Hispaania, Portugali, Poola, Saksamaa ja Ühendkuningriigi tõstatatud probleemi tõttu, et põrsaste ravimi CEVAZURIL 50 mg/ml suukaudse suspensiooni müügiloaga võib kaasneda suur keskkonnarisk, Euroopa Ravimiametile direktiivi 2001/82/EÜ artikli 33 lõike 4 kohase esildise.
English: referral for CEVAZURIL 50 mg/ml oral suspension for piglets
Estonian: Arvamus pärast artikli 33 lõike 41 kohast esildist CEVAZURIL 50 mg/ml suukaudne suspensioon põrsastele
English: On this basis, no further revisions were warranted.
Estonian: Selle tõttu ei olnud muid muudatusi vaja.
English: Lyme Borreliosis
Estonian: Lyme'i borrelioos
English: Other indications
Estonian: Muud näidustused
English: Overall summary of the scientific evaluation of Rocephin and associated names (see Annex I)
Estonian: Ravimi Rocephin ja sarnaste nimetuste (vt I lisa) teadusliku hindamise üldkokkuvõte
English: Section 5.2 - Pharmacokinetic properties
Estonian: Lõik 5.2 Farmakokineetilised omadused
English: Dose recommendations have been listed in tabular format according to dosage schedules for each indication for: Adults and children over 12 years of age (≥ 50 kg), Neonates, infants and children 15 days to 12 years of age (< 50 kg) and Neonates 0-14 days.
Estonian: Annustamissoovitused on esitatud tabelina iga näidustuse kohta järgmistes vanuserühmades: täiskasvanud ja üle 12-aastased lapsed (≥ 50 kg); vastsündinud, imikud ja lapsed vanuses 15 päeva kuni 12 aastat (< 50 kg); vastsündinud vanuses 0-14 päeva.
English: Syphilis including neurosyphilis
Estonian: Süüfilis, sealhulgas neurosüüfilis
English: One paediatric study was also submitted by the MAH, which enrolled 48 patients aged 2 months to 5 years.
Estonian: Müügiloa hoidja esitas ka ühe pediaatrilise uuringu andmed, milles osales 48 patsienti vanuses 2 kuud kuni 5 aastat.
English: The half-life increases in the elderly, and in older people aged over 75 years the average elimination half-life is usually two to three times that of young adults.
Estonian: Eakatel patsientidel on tseftriaksooni poolväärtusaeg üldiselt pikem ja näiteks üle 75-aastastel patsientidel on keskmine eritumise poolväärtusaeg 2-3 korda pikem kui noortel täiskasvanutel.
English: Bacteraemia
Estonian: Baktereemia
English: In addition the draft addendum to the Note for guidance on evaluation of medicinal products indicated for treatment of bacterial infections (CPMP/EWP/558/95 rev 2) refers to IAI only.
Estonian: Samuti nimetab bakterinfektsioonide raviks näidustatud ravimite hindamise suunise lisa kavand (CPMP/EWP/558/95 rev 2) üksnes kõhuõõne infektsioone.
English: Gonorrhoea, gonococcal arthritis, gonococcal eye infection
Estonian: Gonorröa, gonokokkartriit ja silma gonokokknakkus
English: The elimination half-life of total ceftriaxone in adults is about 8 hours.
Estonian: Kogu tseftriaksooni eritumise poolväärtusaeg on ligikaudu 8 tundi.
English: Bacterial Meningitis
Estonian: Bakteriaalne meningiit
English: There is a low incidence of cross allergy between penicillins and 2nd or 3rd generation cephalosporins.
Estonian: Penitsilliinide ja 2. või 3. põlvkonna tsefalosporiinide vahelise ristallergia esinemissagedus on väike.
English: At the request of the CHMP, information on drug-drug interactions (DDI) with anticoagulants was included, with a recommendation that the INR (international normalised ratio) is monitored frequently.
Estonian: Inimravimite komitee nõudel lisati teave ravimivaheliste koostoimete kohta antikoagulantidega koos soovitusega jälgida sageli suuruse INR (rahvusvaheline standardsuhe) väärtust.
English: Information on absorption, distribution, metabolism and elimination has been provided.
Estonian: Esitatud on imendumise, jaotumise, biotransformatsiooni ja eritumise teave.
English: The MAH's proposal ‘Infections in patients with impaired defence mechanisms' was not considered to be sufficiently supported by data.
Estonian: Müügiloa hoidja välja pakutud näidustuse sõnastust „infektsioonid nõrgestatud kaitsemehhanismidega patsientidel” ei peetud olemasolevate andmete alusel piisavalt tõendatuks.
English: Taking into account the additional amendments to bring the wording is in line with the recommendations made in the Guideline on the Summary of Product Characteristics (2009), this section was considered to be acceptable by the CHMP.
Estonian: Koos muude muudatustega, mida tehti lõigu sõnastuse vastavusse viimiseks ravimi omaduste kokkuvõtte suunise (2009) soovitustega, pidas inimravimite komitee lõiku vastuvõetavaks.
English: It is stated that the treatment of overdose should be symptomatic.
Estonian: Samuti märgitakse lõigus, et üleannustamise ravi on sümptomaatiline.
English: ‘Purpura fulminans' was deleted as an indication as it was agreed that the condition is a manifestation of specific infections, all of which are already covered in the list of indications.
Estonian: Samuti eemaldati näidustus „fulminantne purpur”, sest see haigusseisund on spetsiifiliste infektsioonide avaldumine, mis kõik on juba kaetud näidustustega.
English: Ceftriaxone has been shown to be beneficial in both early (Stage II) and late (Stage III) disseminated Lyme borreliosis and is recommended in current clinical guidelines.
Estonian: On näidatud, et tseftriaksoon on kasulik nii varase (II staadium) kui ka hilise (III staadium) dissemineerunud Lyme'i borrelioosi ravis ja ühtlasi soovitavad selle kasutamist kehtivad ravisuunised.
English: Due to the divergent national decisions taken by Member States concerning the authorisation of Rocephin and associated names, the European Commission notified the EMA of an official referral under Article 30 of Directive 2001/83/EC in order to resolve divergences amongst the nationally authorised product informations for the above-mentioned products and thus to harmonise them across the EU.
Estonian: Et liikmesriikide otsused Rocephini ja sarnaste nimetuste müügiloa andmise kohta erinevad, teatas Euroopa Komisjon Euroopa Ravimiametile direktiivi 2001/83/EÜ artikli 30 kohase ametliku esildise algatamisest, et kõrvaldada erinevused riikliku müügiloaga ravimite omaduste kokkuvõtetes ning seega ühtlustada need kogu Euroopa Liidus.
English: The amended wording was considered to be acceptable by the CHMP.
Estonian: Muudetud sõnastus oli inimravimite komiteele vastuvõetav.
English: The MAH's clinical trial data all stem from open, retrospective or observational uncontrolled studies enrolling small numbers of patients.
Estonian: Kõik müügiloa hoidja kliiniliste uuringute andmed pärinevad avatud, retrospektiivsetest või kontrollita vaatlusuuringutest, milles on osalenud väike arv patsiente.
English: It was noted that the proposal for the indication is aligned with the wording previously agreed on for similar antibiotics.
Estonian: Inimravimite komitee märkis, et kavandatud näidustuse sõnastus on sama, mis on teiste sarnaste antibiootikumide korral juba heaks kiidetud.
English: Current guidelines require indications to be specific where possible, as it was recognised that different clinical conditions summarised under LRTI have different etiology and therefore may require different treatment.
Estonian: Praeguste suuniste kohaselt peavad näidustused olema võimaluse korral spetsiifilised, sest mõiste „alumiste hingamisteede infektsioonid” koondab mitmesuguseid kliinilisi seisundeid, millel on eri etioloogia ja mis võivad seepärast vajada erinevat ravi.
English: Rocephin is approved in 19 EU Member States with different nationally approved Summaries of Product Characteristics (SmPCs).
Estonian: Rocephin on heaks kiidetud Euroopa Liidu 19 liikmesriigis ja riiklike menetluste kaudu antud müügilubade ravimi omaduste kokkuvõtted erinevad.
English: Prophylaxis of perioperative infections
Estonian: Perioperatiivsete infektsioonide profülaktika
English: The conclusions of the harmonisation of the different sections of the SmPC are summarised below.
Estonian: Ravimi omaduste kokkuvõtte lõikude ühtlustamise tulemused on järgmised.
English: Taking into account the data from clinical studies and considerable clinical experience with ceftriaxone in the treatment of meningitis in adults and children the CHMP agreed with the harmonised indication of “Bacterial meningitis”.
Estonian: Arvestades kliiniliste uuringute andmeid ja ulatuslikku kliinilist kogemust tseftriaksooni kasutamisel meningiidi ravis täiskasvanutel ja lastel, leppis inimravimite komitee kokku ühtlustatud näidustuse „bakteriaalne meningiit”.
English: This section also states that ceftriaxone solutions containing lidocaine should never be administered intravenously.
Estonian: Lõigus on ka teave, et lidokaiini sisaldavaid tseftriaksoonilahuseid ei tohi mingil juhul manustada intravenoosselt.
English: Rocephin can be administered by intravenous infusion over at least 30 minutes (preferred route) or by slow intravenous injection over 5 minutes, or by deep intramuscular injection.
Estonian: Rocephini manustatakse vähemalt 30-minutise intravenoosse infusioonina (soovitatav manustamisviis), 5-minutise aeglase intravenoosse süstena või sügava intramuskulaarse süstena.
English: However the changes are generally small and dose reduction is not required if renal and hepatic function is satisfactory.
Estonian: Muutused on siiski üldiselt väiksed ning rahuldava neeru- ja maksafunktsiooniga patsientidel ei ole vaja annust vähendada.
English: Data to determine the frequency of Rocephin adverse drug reactions was derived from clinical trials.
Estonian: Andmed Rocephini kõrvaltoimete esinemissageduse kohta pärinesid kliinilistest uuringutest.
English: Based on the above, the CHMP considers the benefit/risk ratio of Rocephin and associated names to be favourable and the harmonised Product Information documents to be approvable.
Estonian: Eespool kirjeldatust lähtudes leiab inimravimite komitee, et Rocephini ja sarnaste nimetuste kasulikkus on suurem kui kaasnevad riskid ning et ravimiteabe ühtlustatud dokumendid võib heaks kiita.
English: In case a lidocaine solution is used as a solvent, ceftriaxone solutions must only be used for intramuscular injection.
Estonian: Kui lahustina kasutatakse lidokaiini, tohib tseftriaksoonilahust kasutada üksnes intramuskulaarseks süsteks.
English: Section 5.3 - Preclinical safety data
Estonian: Lõik 5.3 Prekliinilised ohutusandmed
English: From the data presented for the various indications it appears that sufficient patients with bacteraemia were included in the clinical studies, which allow the conclusion that ceftriaxone can be used in the authorised indications when bacteraemia is present.
Estonian: Mitme näidustuse toetuseks esitatud andmetest ilmneb, et kliinilistes uuringutes osales piisav arv baktereemiaga patsiente, millest võib järeldada, et tseftriaksooni tohib heakskiidetud näidustustel kasutada ka siis, kui patsiendil on baktereemia.
English: However, the use of ceftriaxone has been precluded if the patient has a history of a severe immediate hypersensitivity reaction to any other beta-lactam agent or any other cephalasporin.
Estonian: Tseftriaksooni kasutamist tuleb siiski vältida, kui patsiendil on anamneesis raske vahetu ülitundlikkusreaktsioon mis tahes teisele beetalaktaamantibiootikumile või tsefalosporiinile.
English: Solvent vials contain either sterile water for injections or 1% lidocaine hydrochloride solution.
Estonian: Lahustiviaalid sisaldavad steriilset süstevett või lidokaiinvesinikkloriidi 1% lahust.
English: Ceftriaxone distributes primarily into the extracellular space.
Estonian: Tseftriaksoon jaotub eelkõige rakuvälisesse ruumi.
English: The MAH's proposed text was accepted with minor re-wording.
Estonian: Müügiloa hoidja pakutud tekst oli pärast vähest ümbersõnastamist vastuvõetav.
English: Nevertheless, ceftriaxone has a place where intravenous treatment is needed.
Estonian: Tseftriaksoonil on siiski oma koht kliinilises praktikas, kui on vaja intravenoosset ravi.